A clinical analysis of 25 cases of multiple myeloma compficated by extramedullary plasmacytomas
10.3760/cma.j.issn.0578-1426.2009.05.012
- VernacularTitle:多发性骨髓瘤伴髓外浸润25例临床分析
- Author:
Yuping ZHONG
;
Shilun CHEN
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Neoplasm invasiveness;
Antineoplastic combined chemotherapy protocols
- From:
Chinese Journal of Internal Medicine
2009;48(5):396-398
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical features of multiple myeloma (MM) complicated by extramedullary plasmacytomas(EM). Methods Twenty five patients were enrolled into the study. The proportion male to famale was 15:10 and the median age 55. 2 years. The distribution of different isotypes was IgA ten, IgG nine and light chain λ five. The sites of complicating plasmacytoma included muscle, bone, skin, rectum, and testicles. The most common site was muscle. Results Patients with complicated extramedullary plasmacytomas at the time of diagnosis received traditional treatment, including vincristiuum, adriamycin, dexamethasonum, mephalan, presnisone, thalidomide and bortezomib. Rates of overall response (ORR) were 80%. Plasmacytomas occurring after the diagnosis of MM received cisplatin, etoposide, cyclophosphamide, presnisone, or bortezomib ORR were 66. 7% ,50. 0%. Conclusion These results lend support to the efficacy of bortezomib in the treatment of plasmacytoma. MM cases with unconventional disease recurrence are likely to be seen due to sub-clinical seeding of turnout cells suggestive of the presence of an EM clone of plasma cells with a high degree of chemoresistance. Available data in the literature concerning the optimal therapy for patients with EM relapse were reviewed.
